Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
B06AX07
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:firstDoseSchedule |
weeks 0, 2, then every 4 weeks
|
| gptkbp:form |
solution for infusion
5 mg/kg |
| gptkbp:frequency |
every 4 weeks after initial doses
|
| gptkbp:genericName |
gptkb:crizanlizumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adakveo
|
| gptkbp:indication |
sickle cell disease
prevention of vaso-occlusive crises |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
P-selectin inhibitor
|
| gptkbp:molecularWeight |
146 kDa
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea back pain arthralgia infusion-related reactions |
| gptkbp:target |
gptkb:P-selectin
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|